Compare TGT & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGT | IQV |
|---|---|---|
| Founded | 1902 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7B | 36.4B |
| IPO Year | N/A | 2013 |
| Metric | TGT | IQV |
|---|---|---|
| Price | $96.96 | $225.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 27 | 17 |
| Target Price | $101.04 | ★ $237.59 |
| AVG Volume (30 Days) | ★ 7.9M | 1.4M |
| Earning Date | 11-19-2025 | 10-28-2025 |
| Dividend Yield | ★ 4.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.25 | 7.30 |
| Revenue | ★ $105,242,000,000.00 | $15,904,000,000.00 |
| Revenue This Year | N/A | $6.14 |
| Revenue Next Year | $1.77 | $5.35 |
| P/E Ratio | ★ $11.75 | $30.94 |
| Revenue Growth | N/A | ★ 3.85 |
| 52 Week Low | $83.44 | $134.65 |
| 52 Week High | $145.08 | $234.30 |
| Indicator | TGT | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 66.12 | 55.28 |
| Support Level | $90.17 | $217.86 |
| Resistance Level | $92.91 | $230.80 |
| Average True Range (ATR) | 2.60 | 5.52 |
| MACD | 0.88 | -1.08 |
| Stochastic Oscillator | 98.15 | 53.14 |
Target's start dates back to 1962, but now it is one of the largest discount retailers in the United States (where it derives all of its sales), operating just under 2,000 stores and generating over $106 billion in fiscal 2024 sales. The company offers a broad assortment of merchandise across categories including apparel and accessories (16% of fiscal 2024 revenue), beauty and household essentials (30%), food and beverage (23%), hardlines (15%), as well as home furnishings (16%). Target's model is anchored in its physical store base, which fulfills more than 97% of sales. Around 30% of sales are derived from its own private-label brands.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.